Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Chief Medical Officer | October 04, 2021 | October 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date October 04, 2021 · Filed October 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 453,529 |
Ending reported balance
After 2021-10-04 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-10-04 · Sale · Disposed 10,678 · Balance 461,540 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.78 to $23.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 2 · 2021-10-04 · Sale · Disposed 4,711 · Balance 456,829 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.78 to $24.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 3 · 2021-10-04 · Sale · Disposed 2,967 · Balance 453,862 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.78 to $25.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 4 · 2021-10-04 · Sale · Disposed 333 · Balance 453,529 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.795 to $26.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.78 to $23.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.78 to $24.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.78 to $25.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.795 to $26.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Forma Therapeutics Holdings, Inc.
Report date October 14, 2022 · Filed October 14, 2022
Section 16 reporting ended · disclosed 2022-10-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 1
1 source rowRow 1 · 2022-10-14 · Other · Disposed 79,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-14 · Disposition to issuer · Disposed 118,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.
F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2022 Filed Oct 14, 2022 16:06 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | Disposition to issuerStock Option (Right to Buy) · Derivative | 118,000 | Not disclosed Strike: $8.20 | Not disclosed |
DisclosureSEC source: 0000899243-22-033653 · doc4.xml · derivative · entry 2 Melian Agustin · CIK 0001818064 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 118,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 16:06 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | OtherCommon Stock | 79,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033653 · doc4.xml · nonDerivative · entry 1 Melian Agustin · CIK 0001818064 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F2 · kind: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. F2 · shares: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. F2 · price: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. Read SEC document |
| July 11, 2022 Filed Jul 12, 2022 16:24 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantStock Option (Right to Buy) · Derivative | 118,000 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0000899243-22-025976 · doc4.xml · derivative · entry 2 Melian Agustin · CIK 0001818064 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2032-07-10 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on July 11, 2023, and the remainder of the shares shall vest in equal monthly installments for a period of 36 months thereafter. Read SEC document |
| July 11, 2022 Filed Jul 12, 2022 16:24 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantCommon Stock | 79,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-025976 · doc4.xml · nonDerivative · entry 1 Melian Agustin · CIK 0001818064 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,000 F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 21:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 333 | $26.02 | $8,665.79 |
DisclosureSEC source: 0000899243-21-039356 · doc4.xml · nonDerivative · entry 4 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,529 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.795 to $26.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 21:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,967 | $25.41 | $75,377.23 |
DisclosureSEC source: 0000899243-21-039356 · doc4.xml · nonDerivative · entry 3 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,862 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.78 to $25.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 21:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,711 | $24.23 | $114,129.16 |
DisclosureSEC source: 0000899243-21-039356 · doc4.xml · nonDerivative · entry 2 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,829 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.78 to $24.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 21:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 10,678 | $23.29 | $248,689.55 |
DisclosureSEC source: 0000899243-21-039356 · doc4.xml · nonDerivative · entry 1 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,540 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.78 to $23.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 28, 2021 Filed Sep 29, 2021 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,750 | $24.12 | $90,432.38 |
DisclosureSEC source: 0000899243-21-038191 · doc4.xml · nonDerivative · entry 1 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,218 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 16:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,950 | $24.01 | $70,841.89 |
DisclosureSEC source: 0000899243-21-036577 · doc4.xml · nonDerivative · entry 4 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,968 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 15, 2021 Filed Sep 20, 2021 16:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 800 | $24.03 | $19,224.00 |
DisclosureSEC source: 0000899243-21-036577 · doc4.xml · nonDerivative · entry 3 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,918 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 02, 2021 Filed Sep 20, 2021 16:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 18,586 | $19.99 | $371,534.14 |
DisclosureSEC source: 0000899243-21-036577 · doc4.xml · nonDerivative · entry 2 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,718 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. Read SEC document |
| April 05, 2021 Filed Sep 20, 2021 16:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 18,212 | $23.89 | $435,084.68 |
DisclosureSEC source: 0000899243-21-036577 · doc4.xml · nonDerivative · entry 1 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498,304 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 16:53 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,750 | $25.97 | $97,393.50 |
DisclosureSEC source: 0001209191-21-022860 · doc4.xml · nonDerivative · entry 1 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,516 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.52 to $26.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 16:35 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 54,849 | $41.19 | $2,259,230.31 |
DisclosureSEC source: 0000899243-21-004953 · doc4.xml · nonDerivative · entry 1 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,266 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 19:28 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 81,250 | $0.00 Strike: $42.15 | $0.00 |
DisclosureSEC source: 0000899243-21-002767 · doc4.xml · derivative · entry 2 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,250 Underlying: Common Stock · 81,250 shares Expires 2031-01-19 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 19:28 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002767 · doc4.xml · nonDerivative · entry 1 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,115 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 18:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 220,700 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020933 · doc4.xml · derivative · entry 1 Melian Agustin · CIK 0001818064 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,700 Underlying: Common Stock · 220,700 shares Expires 2030-07-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on July 29, 2021, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.